CDSCO Panel Clears AstraZeneca's Datopotamab for Breast Cancer, Seeks Phase IV Trial Parthika Patel19 July 2025 7:33 PMNew Delhi: The Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organisation (CDSCO) has granted...
Baxdrostat Significantly Lowers Blood Pressure in Resistant Hypertension in Phase 3 trial Dr. Prem Aggarwal17 July 2025 3:30 AMAstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III...
Expert Panel Approves Post-Marketing Surveillance Study of Eculizumab (Soliris) by AstraZeneca in India Dr. Divya Colin6 July 2025 9:30 AMNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to...
AstraZeneca Imfinzi approved in EU for muscle-invasive bladder cancer Ruchika Sharma6 July 2025 5:30 AMCambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult patients...
AstraZeneca expands Global Hub in Bangalore with Rs 166 crore investment Ruchika Sharma29 Jun 2025 11:00 AMThe hub is designed to achieve LEED Platinum certification and is currently powered by 75% green energy.
AstraZeneca-Daiichi Sankyo Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer Ruchika Sharma26 Jun 2025 5:50 AMCambridge: AstraZeneca and Daiichi Sankyo have announced that Datroway (datopotamab deruxtecan or Dato-DXd) has...
Label Update for AstraZeneca's Olaparib Cleared by CDSCO Panel Parthika Patel25 Jun 2025 11:41 AMNew Delhi: In a recent regulatory update, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control...
CORONA Remedies appoints four Independent Directors to its board Ruchika Sharma24 Jun 2025 9:45 AMAhmedabad: CORONA Remedies Limited, backed by Sepia Investments Limited, an affiliate of ChrysCapital, has appointed Ameetkumar Hiranyakumar...
AstraZeneca's Oral PCSK9 Inhibitor AZD0780 Cleared for Phase III Trial by CDSCO Panel Dr. Divya Colin22 Jun 2025 4:00 AMNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to AstraZeneca Pharma...
AstraZeneca collaborates with CSPC Pharma focused on AI-enabled research Ruchika Sharma15 Jun 2025 5:30 AMCambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.Working...
CDSCO Panel Approves Updated Prescribing Information for AstraZeneca's Rosuvastatin (Crestor) Dr. Divya Colin8 Jun 2025 7:13 AMNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval for the updated...
AstraZeneca Calquence based regimens approved in EU for previously untreated chronic lymphocytic leukaemia Ruchika Sharma6 Jun 2025 6:58 AMA fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has received...
